(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | (FY)Dec 31, 2021 | (Q9)Sep 30, 2021 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 6.30%1.32B | 30.51%2.68B | 31.51%1.24B | 25.50%565.86M | 26.53%2.05B | 24.61%1.49B | 19.42%945.18M | 10.18%450.89M | 42.84%1.62B | 56.15%1.19B |
Operating income | 6.30%1.32B | 30.51%2.68B | 31.51%1.24B | 26.53%2.05B | 24.61%1.49B | 19.42%945.18M | 42.84%1.62B | 56.15%1.19B | ||
Cost of sales | -2.07%-354.19M | -26.76%-726.38M | -29.67%-347M | ---- | -33.63%-573.06M | ---- | -24.93%-267.6M | ---- | -43.71%-428.84M | ---- |
Operating expenses | -2.07%-354.19M | -26.76%-726.38M | -29.67%-347M | -33.63%-573.06M | -24.93%-267.6M | -43.71%-428.84M | ||||
Gross profit | 7.94%967.16M | 31.96%1.95B | 32.24%896.03M | 23.98%1.48B | 17.38%677.58M | 42.53%1.19B | ||||
Selling expenses | -9.95%-506.54M | -36.75%-1.07B | -18.60%-460.68M | ---- | -36.23%-784.64M | ---- | -63.38%-388.44M | ---- | -31.04%-575.99M | ---- |
Administrative expenses | -12.87%-139.94M | 3.96%-259.28M | 6.45%-123.98M | ---- | -2.75%-269.98M | ---- | -6.74%-132.53M | ---- | -31.48%-262.76M | ---- |
Research and development expenses | -11.79%-225.88M | -2.47%-378.79M | -26.33%-202.07M | ---- | -46.68%-369.65M | ---- | -40.22%-159.95M | ---- | -25.36%-252.01M | ---- |
Impairment and provision | -325.98%-10.99M | -95,810.84%-79.61M | -28,555.56%-2.58M | ---- | 69.93%-83K | ---- | 95.63%-9K | ---- | 46.62%-276K | ---- |
-Other impairment is provision | -325.98%-10.99M | -95,810.84%-79.61M | -28,555.56%-2.58M | ---- | 69.93%-83K | ---- | 95.63%-9K | ---- | 46.62%-276K | ---- |
Special items of operating profit | -30.43%73.03M | 2.76%182.89M | 10.09%104.98M | ---- | 7,638.37%177.98M | ---- | 395.74%95.36M | ---- | -106.82%-2.36M | ---- |
Operating profit | -25.92%156.83M | 47.72%346.77M | 130.07%211.7M | 131.89%234.75M | 33.67%92.01M | 218.10%101.23M | ||||
Financing income | -25.65%2.11M | -15.47%5.76M | -24.68%2.84M | ---- | -15.08%6.81M | ---- | 15.70%3.77M | ---- | --8.02M | ---- |
Financing cost | 52.88%-3.57M | -25.67%-16.31M | -20.88%-7.58M | ---- | -50.77%-12.98M | ---- | -37.02%-6.27M | ---- | 15.29%-8.61M | ---- |
Share of profits of associates | -5,909.09%-1.92M | ---- | --33K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Special items of earning before tax | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -2,695.45%-3.7B | ---- |
Earning before tax | -25.86%153.46M | 47.08%336.22M | 131.24%206.99M | 106.36%228.59M | 102.47%89.52M | -3,152.03%-3.6B | ||||
Tax | -5,642.70%-10.62M | -233.43%-958K | -104.80%-185K | ---- | 109.72%718K | ---- | 142.30%3.85M | ---- | -580.99%-7.39M | ---- |
After-tax profit from continuing operations | -30.93%142.83M | 46.21%335.26M | 121.49%206.81M | 106.36%229.31M | 102.57%93.37M | -3,204.60%-3.6B | ||||
Earning after tax | -30.93%142.83M | 46.21%335.26M | 121.49%206.81M | 106.36%229.31M | 102.57%93.37M | -3,204.60%-3.6B | ||||
Minority profit | 84.78%2.88M | 49.79%-5.2M | 128.03%1.56M | ---- | -918.29%-10.36M | ---- | -284.86%-5.56M | ---- | -168.07%-1.02M | ---- |
Profit attributable to shareholders | -31.81%139.96M | 42.06%340.46M | 107.48%205.25M | 106.65%239.66M | 102.72%98.93M | -3,159.03%-3.6B | ||||
Basic earnings per share | -30.23%0.3 | 44.00%0.72 | 104.76%0.43 | 105.46%0.5 | 101.79%0.21 | -1,030.86%-9.16 | ||||
Diluted earnings per share | -29.27%0.29 | 44.68%0.68 | 115.79%0.41 | 105.13%0.47 | 101.62%0.19 | -1,030.86%-9.16 | ||||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | Unqualified Opinion | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- |
Auditor | -- | KPMG | -- | -- | KPMG | -- | -- | -- | KPMG | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data
No Data